Selami Demirci

Selami Demirci

Auto-generated profile, based on publicly available information

Selami Demirci

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
SDSelami Demirci
Selami Demirci
ALAlexis Leonard
Alexis Leonard
JTJohn F. Tisdale
John F. Tisdale
The generation of hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) is an active and promising area of research; however, generating engraftable HSCs remains a major obstacle. Ex vivo HSC derivation from renewable sources such as iPSCs offers an experimental tool for studying developmental hematopoiesis, disease modeling, and drug discovery, and yields tremendous therapeutic potential for malignant and nonmalignant hematological disorders. Although initial attempts mostly recapitulated yolk sac primitive/definitive hematopoiesis with inability to engraft, recent advances suggest the feasibility of engraftable HSC derivation from iPSCs utilizing ectopic transcription factor expression. Strategic development for de novo HSC generation includes further investigations of HSC ontogeny, and elucidation of critical signaling pathways, epigenetic modulations, HSC and iPSC microenvironment, and cell-cell interactions that contribute to stem cell biology and function.Significance statement Patient-specific hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) offer possibility for the treatment of hematological diseases, particularly when no other options are available. This review highlights the current advances in HSC derivation from PSCs and discusses the obstacles that need to be overcome for future autologous PSC-derived HSC transplantation as a therapeutic modality. The feasibility of HSC generation from transcription factor engineered PSCs has been demonstrated in laboratory conditions and is suggestive of clinically relevant application.

1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SDSelami Demirci
Selami Demirci
JZJing Zeng
Jing Zeng
YWYuxuan Wu
Yuxuan Wu
NUNaoya Uchida
Naoya Uchida
ASAnne H. Shen
Anne H. Shen
JTJohn F. Tisdale
John F. Tisdale
Gene editing of the erythroid-specific BCL11A enhancer in hematopoietic stem and progenitor cells (HSPCs) from patients with sickle cell disease (SCD) induces fetal hemoglobin (HbF) without detectable toxicity, as assessed by mouse xenotransplant. Here, we evaluated autologous engraftment and HbF induction potential of erythroid-specific BCL11A enhancer–edited HSPCs in 4 nonhuman primates. We used a single guide RNA (sgRNA) with identical human and rhesus target sequences to disrupt a GATA1 binding site at the BCL11A +58 erythroid enhancer. Cas9 protein and sgRNA ribonucleoprotein complex (RNP) was electroporated into rhesus HSPCs, followed by autologous infusion after myeloablation. We found that gene edits persisted in peripheral blood (PB) and bone marrow (BM) for up to 101 weeks similarly for BCL11A enhancer– or control locus–targeted (AAVS1-targeted) cells. Biallelic BCL11A enhancer editing resulted in robust γ-globin induction, with the highest levels observed during stress erythropoiesis. Indels were evenly distributed across PB and BM lineages. Off-target edits were not observed. Nonhomologous end-joining repair alleles were enriched in engrafting HSCs. In summary, we found that edited HSCs can persist for at least 101 weeks after transplant and biallelic-edited HSCs provide substantial HbF levels in PB red blood cells, together supporting further clinical translation of this approach.

1 April 2017 in Metabolism
Verified
Journal Article
Closed access
Ayşegül DoğanAyşegül Doğan
Ayşegül Doğan
SDSelami Demirci
Selami Demirci
HAHüseyin Apdik
Hüseyin Apdik
OBOmer Faruk Bayrak
Omer Faruk Bayrak
SGSukru Gulluoglu
Sukru Gulluoglu
FŞFikrettin Şahin
Fikrettin Şahin

5 February 2019
Verified
Book Chapter
Closed access
PDF file
SDSelami Demirci
Selami Demirci
ALAlexis Leonard
Alexis Leonard
JHJuan J. Haro-Mora
Juan J. Haro-Mora
NUNaoya Uchida
Naoya Uchida
JTJohn F. Tisdale
John F. Tisdale

12 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NUNaoya Uchida
Naoya Uchida
USUlana Stasula
Ulana Stasula
SDSelami Demirci
Selami Demirci
PGPaula Germino-Watnick
Paula Germino-Watnick
MHMalikiya Hinds
Malikiya Hinds
JTJohn F. Tisdale
John F. Tisdale
Hematopoietic stem cell (HSC) gene therapy has curative potential; however, its use is limited by the morbidity and mortality associated with current chemotherapy-based conditioning. Targeted conditioning using antibody-drug conjugates (ADC) holds promise for reduced toxicity in HSC gene therapy. Here we test the ability of an antibody-drug conjugate targeting CD117 (CD117-ADC) to enable engraftment in a non-human primate lentiviral gene therapy model of hemoglobinopathies. Following single-dose CD117-ADC, a >99% depletion of bone marrow CD34 + CD90 + CD45RA- cells without lymphocyte reduction is observed, which results are not inferior to multi-day myeloablative busulfan conditioning. CD117-ADC, similarly to busulfan, allows efficient engraftment, gene marking, and vector-derived fetal hemoglobin induction. Importantly, ADC treatment is associated with minimal toxicity, and CD117-ADC-conditioned animals maintain fertility. In contrast, busulfan treatment commonly causes severe toxicities and infertility in humans. Thus, the myeloablative capacity of single-dose CD117-ADC is sufficient for efficient engraftment of gene-modified HSCs while preserving fertility and reducing adverse effects related to toxicity in non-human primates. This targeted conditioning approach thus provides the proof-of-principle to improve risk-benefit ratio in a variety of HSC-based gene therapy products in humans.

1 October 2021 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
SDSelami Demirci
Selami Demirci
ALAlexis Leonard
Alexis Leonard
KEKhaled Essawi
Khaled Essawi
JTJohn F. Tisdale
John F. Tisdale
Genome editing is potentially a curative technique available to all individuals with β-hemoglobinopathies, including sickle cell disease (SCD). Fetal hemoglobin (HbF) inhibits sickle hemoglobin (HbS) polymerization, and it is well described that naturally occurring hereditary persistence of HbF (HPFH) alleviates disease symptoms; therefore, reawakening of developmentally silenced HbF in adult red blood cells (RBCs) has long been of interest as a therapeutic strategy. Recent advances in genome editing platforms, particularly with the use of CRISPR-Cas9, have paved the way for efficient HbF induction through the creation of artificial HPFH mutations, editing of transcriptional HbF silencers, and modulating epigenetic intermediates that govern HbF expression. Clinical trials investigating BCL11A enhancer editing in patients with β-hemoglobinopathies have demonstrated promising results, although follow-up is short and the number of patients treated to date is low. While practical, economic, and clinical challenges of genome editing are well recognized by the scientific community, potential solutions to overcome these hurdles are in development. Here, we review the recent progress and obstacles yet to be overcome for the most effective and feasible HbF reactivation practice using CRISPR-Cas9 genome editing as a curative strategy for patients with SCD.